Yes. Do exactly that--and then see now NOT mentioned BTX is in the field.
Or watch the youtube vid from actc and then look at its chart since last november, and then look at the change in o/s in the same time period.
The availability of iPS cells will no doubt increase the number of research grade ES-like cell lines dramatically and may ultimately fulfill the need for patient specific stem cells. However, a significant problem and potential bottleneck to developing stem cell therapies is the development of efficient tools and technologies for directed differentiation of pluripotent stem cells toward therapeutic cell types. Currently, this process is poorly understood and often yields differentiated cells that represent only a few percent of the starting ES cells which are difficult to scale up.
Buy in before PanC-DxTM becomes a reality. Figure everyone will jump on this bandwagon in 2014 when Biotime launches this product at Cornell Weil hospital.
PanC-DxTM is being developed to detect the presence of a variety of human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check-ups. By facilitating early non-invasive cancer detection through a blood test, PanC-DxTM could lead to more successful therapeutic outcomes while simultaneously reducing the costs of cancer monitoring and globally increasing the availability of affordable cancer screening. OncoCyte first announced the development of PanC-DxTM during December 2011 and intends to launch the product in Europe in 2014 before seeking the required approval by the Food and Drug Administration to market PanC-DxTM in the United States.